
    
      PRIMARY OBJECTIVE:

      I. Determine the safety and tolerability of vorinostat in women undergoing conventional
      surgery for newly diagnosed stage I-III breast cancer.

      OULINE: This is a multicenter, pilot study.

      Patients receive oral vorinostat twice daily on days -3 to 0. Approximately 2 hours after the
      final dose of vorinostat, patients undergo surgical resection of the tumor on day 0.

      After completion of study treatment, patients are followed for 30 days.
    
  